Kintara Therapeutics Files 8-K

Ticker: HURA · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1498382

Sentiment: neutral

Topics: 8-K, financial-reporting, operations

Related Tickers: KTRA

TL;DR

KINTARA THERAPEUTICS FILED AN 8-K ON OCT 8TH - FINANCIALS & OPERATIONS UPDATE

AI Summary

Kintara Therapeutics, Inc. filed an 8-K on October 8, 2024, reporting on results of operations, financial condition, and Regulation FD disclosures. The filing also includes financial statements and exhibits. The company was formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc.

Why It Matters

This 8-K filing provides an update on Kintara Therapeutics' financial status and operational results, which is crucial information for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report detailing financial information and operational updates, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Kintara Therapeutics?

The primary purpose is to report on the company's results of operations and financial condition, provide Regulation FD disclosures, and include financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on October 8, 2024.

What were Kintara Therapeutics' previous names?

Kintara Therapeutics, Inc. was formerly known as DelMar Pharmaceuticals, Inc. and Berry Only Inc.

In which state is Kintara Therapeutics incorporated?

Kintara Therapeutics, Inc. is incorporated in Nevada.

What is Kintara Therapeutics' principal executive office address?

The principal executive office is located at 9920 Pacific Heights Blvd, Suite 150, San Diego, CA 92121.

Filing Stats: 1,189 words · 5 min read · ~4 pages · Grade level 14.3 · Accepted 2024-10-08 07:05:07

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. Kintara Therapeutics, Inc. (" Kintara ") issued a press release on October 8, 2024, disclosing financial information and operating metrics for fiscal the year ended June 30, 2024, and providing a corporate update. A copy of Kintara's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. See "Item 2.02 Results of Operations and Financial Condition" above. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the " SEC "), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K and the communication attached hereto as Exhibit 99.1 contain forward-looking statements based upon Kintara's and TuHURA's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. These statements are only predictions. Kintara and TuHURA have based these forward-looking statements largely on their then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond each of Kintara's and TuHURA's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the risk that the conditions to the closing or consummation of the proposed Merger are not satisfied; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Kintara and TuHURA to consummate the transactions contemplated by the proposed Merger; (iii) risks related to Kintara's and TuHURA's ability to correctly estimate their respective operating expenses and expenses associated with the proposed Merger, as applicable, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the resulting combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources; (iv) the occurrence of any event, cha

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release of Kintara Therapeutics, Inc. issued October 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINTARA THERAPEUTICS, INC. Date: October 8, 2024 By: /s/ Robert E. Hoffman Name: Robert E. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing